Search PubMed⌕ Search

Biomedical subjects

W Wuttke

Publications and source records attributed to W Wuttke.

256 records · Page 15Linked to original sources

Electrophysiological and psychological changes induced by steroid hormones in men and women.

The effects of hormonal changes during the menstrual cycle and of oral contraceptives on the EEG, heart-rate and a number of performance tasks were investigated in 16 female subjects (Ss). Powerspectral analysis in the EEG revealed significantly increased alpha-frequencies and heart-rates during the luteal phase of the menstrual cycle whereas the mean theta-frequency and power decreased. A number of psychological test variables, such as reaction time to a tone, to a flickering light and to a colour-tone sequence and the time to solve simple arithmetic problems was shorter at the periovulatory time. Another minimum was reached during the perimenstrual phase. The flicker-fusion-frequency was higher during these two periods. No such effects could be observed when the same Ss were treated with oral contraceptives. It is concluded that the phenomena observed during the luteal phase of the cycle may be the expression of a slight general arousal effect, possibly medicated by progesterone via the noradrenergic system. In a subsequent double blind study 30 male Ss were treated with an gestagenic compound (D-Norgestrel, 2.5 mg/die), an estrogenic compound (estradiolvalerate, 5 mg/die), an androgenic substance (Mesterolone, 100 mg/die) or with placebo. Only treatment with the progestational compound revealed significant changes in the EEG and the performance tests. These changes were qualitatively similar to those observed during the luteal phase of the female Ss. Under both conditions, i.e. the luteal phase and D-Norgestrel treatment, the body-temperature was significantly increased. Hence, the question whether gestagens exert their effects directly on CNS structures which modulate EEG appearance and behavior or indirectly via increased body-temperature cannot be answered convincingly.

Adolescent↗

Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.

BACKGROUND: Elevated serum levels of the oncoprotein p105 (c-erbB-2, HER2/neu) have been found in patients with ovarian cancer, but its role in this disease has not been clearly established. MATERIALS AND METHODS: The authors studied the relationship between p105 serum levels, various tumor parameters, and survival in 57 patients with newly diagnosed, untreated ovarian cancer. Serum specimens were obtained at the time of initial surgery, and p105 levels were determined using the human neu quantitative ELISA assay. RESULTS: Elevated p105 serum levels were correlated with a poor prognosis since patients with low p105 levels had a better survival than patients with high p105 levels (P = 0.02). This result was confirmed in stage III patients (n = 29; P = 0.08). p105 serum levels were not related to tumor stage, grade, histologic findings or serum CA 125 levels. CONCLUSIONS: Our results suggest that ovarian cancer patients with elevated p105 serum levels may have a poor clinical outcome.

Adolescent↗

Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations.

BACKGROUND: In breast and ovarian cancer patients elevated serum levels of the oncoprotein p105 were detected. We examined the influence of endocrine factors on the p105 serum concentration. MATERIALS AND METHODS: The sera of 115 and non-pregnant women were analysed. Of the premenopausal women (n = 77) hormonal contraception was used by 30 women, and of the postmenopausal women (n = 33) there were 15 women using hormonal replacement therapy (HRT). The serum specimens were analysed by ELISA. RESULTS: Women with hormonal contraception had significantly lower serum levels than premenospausal controls (82-138 fmol/ml, median 109 fmol/ml vs. 103-183 fmol/ml, median 130 fmol/ml; P < 0.001). In postmenopausal women with HRT serum levels were significantly lower than in postmenopausal controls (88-136 fmol/ml, median 117 fmol/ml vs. 99-261 fmol/ml, median 148 fmol/ml; P < 0.001). CONCLUSIONS: Sex steroids seem to modulate c-erbB-2 activity. These results are important with regard to clinical studies on p105 oncoprotein in cancer patients.

Contraceptives, Oral, Hormonal↗

Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum.

BACKGROUND: The 105 kDa extracellular domain of c-erbB-2 encoded protein p185 is detectable in serum. Elevated p105 serum levels were found in patients with breast and ovarian cancer and in pregnancy. The effects of interfering and influencing factors on the measurement are still unclear. MATERIAL AND METHODS: We used an ELISA based on the monoclonal capture antibody OD-3 and investigated possible interfering factors, like changing transporting and storing conditions of blood and serum samples. In order to evaluate a normal range of p105 serum values we examined 71 healthy women. RESULTS: In our tests we found no influence on the reproducibility of results by changing transporting and storing conditions. We could not find any dependency of p105 serum values on the menstrual cycle or the age of controls. Postmenopausal women showed significantly higher serum values than premenopausal women (p = 0.0127). CONCLUSIONS: Clinical interpretation of female p105 serum values requires comparison with normal ranges when considering the menopause as an influencing factor.

Adolescent↗